<DOC>
	<DOC>NCT02252159</DOC>
	<brief_summary>This is a Phase IV, multicenter, non-interventional, non-randomized, prospective, observational study in an adult population (patients &gt;18 years old) of men and women who have been diagnosed with clinically overt PV and are being followed in either community or academic medical centers in the United States who will be enrolled over a 12-month period and observed for 36 months from the date the last patient is enrolled.</brief_summary>
	<brief_title>Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Nucleic Acid Synthesis Inhibitors</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Age â‰¥18 years Diagnosis of Polycythemia Vera (PV) Willing and able to provide written informed consent Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel Under the supervision of a physician for the current care of PV including but not limited to watchful waiting, acetylsalicylic acid (ASA) 81mg or greater, antithrombotic therapy, Phlebotomy (PHL), Hydroxyurea (HU), interferon (recombinant or pegylated), busulfan, anagrelide Participation in an active clinical trial in which the study treatment is blinded Life expectancy &lt;6 months Diagnosis of myelofibrosis (MF) [including primary MF, postPV MF, or postessential thrombocythemia MF (postET MF)] Diagnosis of secondary Acute Myeloid Leukemia (AML) Diagnosis of Myelodysplastic Syndrome (MDS) History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months Splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Polycythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antisickling Agents</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>Nucleic Acid Synthesis Inhibitors</keyword>
</DOC>